As part of the multigroup collaboration, process-driven research methodologies will be established at Imperial College through doctoral education and by equipping biofabrication facilities with a digital backbone for laboratory automation and data analytics, according to Riffyn. The partnership will enable Nexus to be used on a large scale in an open academic setting, the company said.

Research groups at the Imperial College's Centre for Synthetic Biology will work with Riffyn to test and develop Nexus for academic research use cases. In addition, Nexus will be implemented across the London Biofoundry SynBio stack. What's more, a new center of excellence will support the training, use, and integration of Nexus across the college's research labs, according to the company. An ongoing educational program will also train doctorate-level students to become expert Nexus users.

Hexagon Bio secures $47M to advance drug discovery platform
Hexagon Bio has closed $47 million in series A financing to advance its drug discovery capabilities on its fungal genomics-based platform.

Making CRISPR safer with new enzyme-based prediction tool
A new technique will help scientists choose the best available gene editing option for any given indication, making CRISPR technology safer, cheaper,...

SwiftScale speeds up the manufacture of COVID-19 antibodies
SwiftScale Biologics said it has used its rapid biologics manufacturing platform to manufacture a COVID-19 neutralizing antibody candidate at clinical...

Spell-check gene editing corrects hearing loss in mice
Using a new genetic engineering technique called base editing, researchers restored genetic hearing loss in mice with a recessive point mutation. The...